INTRODUCTION
With the development of the social economy, all kinds of pressure, the change in lifestyle and the aging population, the incidence of diabetes is increasing year by year. According to incomplete statistics, diabetes patients in China have exceeded the total number of diabetic patients in Europe and the United States, with China ranked second in the world [1, 2] . Diabetes has become a heavy burden of society and family life and to people's health and quality of life. The current situation of the prevention and treatment of diabetes and their complications are serious.
Type 2 diabetes is a chronic, complex metabolic disease [3] . Its pathological mechanism is mainly that the molecular structure of insulin is abnormal or there is an absolute deficiency of insulin secretion, which can cause blood sugar to be unable to enter cells, and sustained high blood glucose levels can cause plasma osmotic pressure to increase significantly, resulting in cellular environment change [4] . Meanwhile, type 2 diabetes can cause disorders of glucose, lipid and protein metabolism, which can result in complications of the heart and peripheral vascular system (such as coronary heart disease and hypertension), endocrine and metabolic system (such as ketoacidosis and lactic acidosis), and others [5, 6] . Among them, type 2 diabetes mellitus complicated with hypertension is a common clinical disease [7, 8] . Studies have shown that for patients with type 2 diabetes and hypertension, the control of blood glucose and blood pressure is more difficult than that of single disease [8, 9] . Moreover, the combination of diseases can damage blood vessels and renal function and increase the risk of vascular disease and renal failure.
Sitagliptin [10] , a dipeptidyl peptidase-4 (DPP-4) inhibitor, is an antihyperglycemic drug that stimulate insulin release from pancreaticβ-cells by sparing incretin hormones. The mechanism of sitagliptin is different from the usual common oral hypoglycemic drugs, and it acts mainly through inhibiting the activity of DPP-4 to prolong the duration of GLP-1 to achieve steady blood sugar. In addition, sitagliptin can protect incretin activity, stimulate islet B-cell regeneration, improve glucose tolerance and insulin sensitivity, and delay the occurrence of diabetes [11] .
However, whether sitagliptin is advantageous to the prognosis of type 2 diabetes patients with hypertension, the conclusion is still controversial. Ogawa S [12] conducted a study lasting six months and determined that sitagliptin can lower SP without reducing body mass index, independent of blood glucose reduction. However, Yuasa S [13] carried out a retrospective cohort study in 454 patients with type 2 diabetes and showed that BP was slightly but significantly reduced after 6 months of sitagliptin therapy, indicating that sitagliptin has pleiotropic effects, including an antihypertensive effect.
The PROLOGUE study [10] was a prospective multicenter study conducted to evaluate the inhibitory effect of a DPP-4 inhibitor on the progression of atherosclerosis based on carotid artery intima-media thickness (IMT) assessed by ultrasonography over a 2-year follow-up period. In the PROLOGUE study, FBS, HbA1c, BP, DP, BUN and SCR were measured in all patients. Thus, we carried out this study as a sub-analysis of the PROLOGUE study to evaluate the long-term effect of sitagliptin in patients with type 2 diabetes mellitus and hypertension. Table 1 shows the baseline clinical characteristics of all patients and the effects of each treatment on baseline parameters in the sitagliptin group and the conventional group. Of the 365 patients, 248 (67.94%) were men and 117 (32.06%) were women. 262 (71.78%) had dyslipidemia, 30 (8.21%) had kidney disease, 17 (4.66%) had liver disease, 52 (14.25%) had a cerebrovascular disorder, 212 (58.08%) had cardiovascular disorder, 42 (11.78%) had cerebral infarction, 3 (0.82%) had cerebral hemorrhage, 5 (1.37%) had transient ischemic attacks, 3 (0.82%) had cerebrovascular disorder, 79 (21.64%) had myocardial infarction, 52 (14.24%) had arrhythmia, 103 (28.22%) had percutaneous coronary intervention, 28 (7.67%) had heart failure, 86 (23.56%) had cardiovascular disorder, 91 (24.93%) had a smoking habit, 40 (10.96%) had a drinking habit, and 27 (7.40%) had a coronary artery bypass graft. There was no significant difference in any of the variables between the two groups, including age, body height, body weight, DBP, SBP, creatinine, heart rate, uric acid, total cholesterol, fasting plasma glucose, HDL, blood urea nitrogen, HBA1C, cystatin-C, triglyceride, waist circumferences, small dense LDL, high molecular weight adiponectin and insulin levels. FBS, HbA1c, BP, DP, BUN and SCR levels after 24 months of treatment Table 3 shows the FBS, HbA1c, BP, DP, BUN and SCR levels after 24 months of treatment. FBS and HbA1c levels were not significantly decreased after 24 months in the sitagliptin group compared to the conventional group [OR: -0.1, 95% CI (-9.1, -8.8) , P=0.979; OR: 0.1, 95% CI (0.0, -0.3), P=0.064, respectively]. BP and DP levels were not significantly decreased after 24 months in the sitagliptin group compared to the conventional group , P=0.775; OR: -1.6, 95% CI (-41, -0.9), P=0204, respectively]. BUN and SCR levels were not significantly decreased after 24 months in the sitagliptin group compared to the conventional group [OR: 0.4, 1.8), P=0.568; P=0.191, respectively] . www.impactjournals.com/oncotarget Results are presented as OR (95% CI) P value. Table 4 shows the subgroup analysis of FBS, HbA1c, BP, DP, BUN and SCR levels after 12 months of treatment. After grouped by history of cardiovascular disorder, history of cerebral infarction, history of myocardial infarction, history of percutaneous coronary intervention and history of coronary artery bypass graft, we did not find that the FBS, HbA1c, BP, DP, BUN or SCR levels in the sitagliptin group were better than those of the conventional group (all P>0.05). Table 5 shows the subgroup analysis of FBS, HbA1c, BP, DP, BUN and SCR levels after 24 months of treatment. After grouped by history of cardiovascular disorder, history of cerebral infarction, history of myocardial infarction, history of percutaneous coronary intervention and history of coronary artery bypass graft, we did not find that the FBS, HbA1c, BP, DP, BUN and SCR levels in the sitagliptin group was better than those of the conventional group (all P>0.05). Table 6 shows the multivariate regression analysis of FBS, HbA1c, BP, DP, BUN and SCR levels after 12 months of treatment. First, the non-adjusted model was not adjusted. Second, the adjust I model was adjusted for age, body height, body weight, DBP, SBP, creatinine, heart rate, uric acid, total cholesterol, fasting plasma glucose, HDL, blood urea nitrogen, HBA1C, cystatin-C, triglyceride, waist circumferences, small dense LDL, high molecular weight adiponectin and insulin. Third, the adjust II model was adjusted for age, body height, body weight, DBP, SBP, Results are presented as OR (95% CI) P value.
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creatinine, heart rate, uric acid, total cholesterol, fasting plasma glucose, HDL, blood urea nitrogen, HBA1C, cystatin-C, triglyceride, waist circumferences, small dense LDL, high molecular weight adiponectin, insulin, history of dyslipidemia, history of kidney disease, history of liver disease, history of cerebrovascular disorder, history of cardiovascular disorder, history of cerebral infarction, history of cerebral hemorrhage, history of transient ischemic attacks, history of cerebrovascular disorder, history of myocardial infarction, history of arrhythmia, history of percutaneous coronary intervention, history of heart failure, history of cardiovascular disorder, smoking habit, drinking habit, and history of coronary artery bypass graft. However, we did not find any differences between the two groups except for in systolic blood pressure at 12 months in the non-adjusted and adjust I analyses in females (P<0.05).
Multivariate regression analysis of FBS, HbA1c, BP, DP, BUN and SCR levels after 24 months of treatment Table 7 shows the multivariate regression analysis of FBS, HbA1c, BP, DP, BUN and SCR levels after 24 months of treatment. First, the non-adjusted model was Results are presented as OR (95% CI) P value. Non-adjusted model adjust for: None. Adjust I model adjust for: age, body height, body weight, DBP, SBP, creatinine, heart rate, uric acid, total cholesterol, fasting plasma glucose, HDL, blood urea nitrogen, HBA1C, cystatin-C, triglyceride, waist circumstances, small dense LDL, high molecular weight adiponectin and insulin. Adjust II model adjust for: age, body height, body weight, DBP, SBP, creatinine, heart rate, uric acid, total cholesterol, fasting plasma glucose, HDL, blood urea nitrogen, HBA1C, cystatin-C, triglyceride, waist circumstances, small dense LDL, high molecular weight adiponectin, insulin, history of dyslipidemia, history of kidney disease, history of liver disease, history of cerebrovascular disorder, history of cardiovascular disorder, history of cerebral infarction, history of cerebral hemorrhage, history of transient ischemic attacks, history of cerebrovascular disorder, history of myocardial infarction, history of arrhythmia, history of percutaneous coronary intervention, history of heart failure, history of cardiovascular disorder, smoking habit, drinking habit, history of coronary artery bypass graft. www.impactjournals.com/oncotarget Results are presented as OR (95% CI) P value. Non-adjusted model adjust for: None. Adjust I model adjust for: age, body height, body weight, DBP, SBP, creatinine, heart rate, uric acid, total cholesterol, fasting plasma glucose, HDL, blood urea nitrogen, HBA1C, cystatin-C, triglyceride, waist circumstances, small dense LDL, high molecular weight adiponectin and insulin. Adjust II model adjust for: age, body height, body weight, DBP, SBP, creatinine, heart rate, uric acid, total cholesterol, fasting plasma glucose, HDL, blood urea nitrogen, HBA1C, cystatin-C, triglyceride, waist circumstances, small dense LDL, high molecular weight adiponectin, insulin, history of dyslipidemia, history of kidney disease, history of liver disease, history of cerebrovascular disorder, history of cardiovascular disorder, history of cerebral infarction, history of cerebral hemorrhage, history of transient ischemic attacks, history of cerebrovascular disorder, history of myocardial infarction, history of arrhythmia, history of percutaneous coronary intervention, history of heart failure, history of cardiovascular disorder, smoking habit, drinking habit, history of coronary artery bypass graft. not adjusted. Second, the adjust I model was adjusted for age, body height, body weight, DBP, SBP, creatinine, heart rate, uric acid, total cholesterol, fasting plasma glucose, HDL, blood urea nitrogen, HBA1C, cystatin-C, triglyceride, waist circumferences, small dense LDL, high molecular weight adiponectin and insulin levels. Third, the adjust II model was adjusted for age, body height, body weight, DBP, SBP, creatinine, heart rate, uric acid, total cholesterol, fasting plasma glucose, HDL, blood urea nitrogen, HBA1C, cystatin-C, triglyceride, waist circumferences, small dense LDL, high molecular weight adiponectin, insulin, history of dyslipidemia, history of kidney disease, history of liver disease, history of cerebrovascular disorder, history of cardiovascular disorder, history of cerebral infarction, history of cerebral hemorrhage, history of transient ischemic attacks, history of cerebrovascular disorder, history of myocardial infarction, history of arrhythmia, history of percutaneous coronary intervention, history of heart failure, history of cardiovascular disorder, smoking habit, drinking habit, and history of coronary artery bypass graft. However, we did not find any differences between the two groups (all P>0.05).
DISCUSSION
To our knowledge, the PROLOGUE study is the largest trial to investigate whether DPP-4 inhibitors (e.g., sitagliptin) slow the progression of carotid IMT in participants with T2DM. The major finding of our study is that there was no evidence that treatment with sitagliptin can improve fasting glucose, HbA1c, systolic pressure or diastolic pressure in type 2 diabetes patients complicated with hypertension during a 2-year study period. In addition, for patients with type 2 diabetes complicated with hypertension, the kidney is one of the most easily damaged organs, which can lead to renal insufficiency and even renal failure. The PROLOGUE study followed up the patients for two years, but our result did not find that sitagliptin has a protective effect on renal function of patients with type 2 diabetes complicated with hypertension, as the changes in serum urea nitrogen and serum creatinine levels were similar to the conventional group. These results may suggest that sitagliptin failed to inhibit fasting glucose, HbA1c, blood pressure and kidney progression relative to the conventional therapy in patients with type 2 diabetes complicated with hypertension, despite its glucose-lowering effect in patients with type 2 diabetes.
It is well known that, with the growth of age and the acceleration of population aging all over the world, the lifetime risk of cardiovascular disease in patients with type 2 diabetes is approximately 67-78% [14] . Management of patients with type 2 diabetes should not only aim to control glycemia but also include the modification of cardiovascular risk factors [15] . Research results showed that hypertension, including essential hypertension and secondary hypertension, affects approximately twothirds of patients with type 2 diabetes and is an important contributing factor to cardiovascular complications [16] . Lowering blood pressure, including systolic and diastolic blood pressure, has been shown to reduce cardiovascular events in patients with type 2 diabetes and to exert a renoprotective effect [17, 18] . In 2003, the Joint National Committee (JNC) guidelines recommended a targets for systolic BP (SBP) of 130 mmHg and diastolic BP (DBP) of 80 mmHg in patients with type 2 diabetes complicated with hypertension [19] . However, the guidelines were recently updated in 2014 to recommend a target BP of 140/90 mmHg in those patients [20] . Therefore, combination therapy is often updated because blood pressure is difficult to control in patients with type 2 diabetes complicated with hypertension [10] .
Sitagliptin, an orally administered dipeptidyl peptidase 4 (DPP-4) inhibitor, prolongs the action of incretin hormones, by inhibiting their breakdown [21] . This improves glycemic control in patients with type 2 diabetes, primarily by suppressing glucagon levels and increasing endogenous insulin secretion. So far, a great deal of results have shown that sitagliptin can significantly improve blood glucose [22] without increasing the risk of fractures [23] or heart failure [24] in patients with type 2 diabetes mellitus. Josse RG [23] et al. conducted a study to assess the association between sitagliptin use and the risk of fractures in type 2 diabetes patients, and 14 671 participants were randomized to sitagliptin (n=7332) or placebo (n=7339) in a double-blind trial. They noted that sitagliptin, compared with placebo, was not associated with a higher fracture risk [adjusted HR 1.03, P =0.745], with major osteoporotic fractures or with hip fractures. Ferreira J C A [25] et al. carried out a trial to evaluate the efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Patients (n=426) were randomized 1:1 to sitagliptin or glipizide, and the results showed that in patients with T2DM and chronic renal insufficiency, sitagliptin and glipizide provided similar A1C-lowering efficacy. However, sitagliptin was generally well-tolerated, with a lower risk of hypoglycemia and weight loss versus weight gain relative to glipizide. All these studies have shown that sitagliptin can significantly improve the prognosis of patients with type 2 diabetes. Nevertheless, studies regarding the effect of sitagliptin on patients with type 2 diabetes complicated with hypertension are scarce. In our study, 365 patients with type 2 diabetes complicated with hypertension were recruited, and our results showed that sitagliptin, compared with conventional treatment, cannot significant improve fasting glucose, HbA1c, systolic pressure, diastolic pressure and renal function in type 2 diabetes patients complicated with hypertension during a 2-year study period (all P>0.05). In addition, compared with conventional treatment, sitagliptin does not have the renal protective effects in those patients. Based www.impactjournals.com/oncotarget on this result, we conducted a sensitivity analysis based on gender, but the results did not change significantly. Our results were different from those of Susumu Ogawa et al. In 2011, Susumu Ogawa [12] conducted a study to estimate whether sitagliptin can decrease systolic blood pressure in Japanese hypertensive patients with type 2 diabetes, and their findings suggest that sitagliptin lowers SBP without reducing BMI, independent of the blood glucose reduction. The hypotensive effect is apparent with the alternate-day regimen of sitagliptin at a lower dose compared to the everyday medication. Chinese scholars [26] conducted a systematic review and meta-analysis to evaluate the effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes, and fifteen trials involving 5636 participants were identified. In addition, the results showed that compared with placebo or nontreatment, DPP-4 inhibitors showed BP-lowering effects for both SBP and DBP. However, no significant differences of associated BP improvement were found between DPP-4 inhibitors and GLP-1 RAs or other antidiabetic medications.
To date, mechanisms related to the antihypertensive effects of DPP4 therapies have not been fully elucidated and some evidence remains inconclusive [27] . Previous studies have suggested complex possible mechanisms, and separate mechanisms may play a role in mediating the BPlowering effects of DPP-4 inhibitors [10] . First, weight loss and improved glycemic control have been indicated to not correlate with the BP-lowering effects. Second, some studies showed that stimulation of natriuresis is one of the core parts contributing to the antihypertensive effects of DPP-4 inhibitors, and vasodilation through GLP-1 receptor-dependent and independent pathways was also considered to be involved in the process. Third, DPP-4 cleaves a number of peptides besides GLP-1, many of which are vasoactive and could be classified into vasodilators and vasoconstrictors in respect of their actions on blood vessels. For example, as substrates of DPP-4, neuropeptide Y 1 (NPY1) and substance P might be related to the BP elevation accompanied with the combined inhibition of angiotensin converting enzyme (ACE) and DPP-4 [28] .
On the other hand, the mechanism of DPP-4 inhibitors, such as sitagliptin, on the protective effect of renal function in type 2 diabetes patients complicated with hypertension remains unclear [29, 30] . Incretinbased agents may exert a beneficial effect in preventing diabetic complications beyond their metabolic effects. Preclinical data have shown that vildagliptin, a DPP-4 inhibitor, can prevent peripheral nerve degeneration in a diabetes-induced animal model. Sitagliptin possesses anti-inflammatory and anti-apoptotic effects in retinal cells and exerts beneficial effects on the blood-retinal barrier integrity in the retinas of Zucker diabetic fatty rats [31] . Many scholars noted that DPP-4 inhibitors increase the availability of GLP-1 in a range of tissues, and GLP-1 receptors are expressed in the proximal tubules, in the renal glomerulus, and on podocytes. Hyperglycemia can impair GLP-1 action and downregulate GLP-1 receptor expression in the kidneys [32] . In human proximal tubular cells, a GLP-1 receptor agonist may inhibit the advanced glycation end product (AGE)-receptor for AGE (RAGE)-mediated asymmetric dimethylarginine generation via inhibition of reactive oxygen species generation, thereby providing protection against the development and progression of diabetic kidney damage [33] . However, we did not find the effect of protective renal function by sitagliptin in our study.
Limitations
There are several limitations of our present study. First, our present study was a sub-analysis of the PROLOGUE study, and the number of study subjects was relatively small. Therefore, there is no sample size for a power calculation since fasting glucose, HbA1c, systolic pressure, diastolic pressure, serum urea nitrogen and serum creatinine were voluntary measured parameters in the PROLOGUE trial, and this may be underpowered. Second, the PROLOGUE study was conducted with a PROBE design, which might have introduced bias in the assessment of outcomes. Third, the patients of our study are Japanese, and perhaps race, gene polymorphism, diet and other factors also dictate the effects of sitagliptin in patients with type 2 diabetes complicated with hypertension. Fourth, baseline fasting glucose, HbA1c, systolic pressure, diastolic pressure, serum urea nitrogen and serum creatinine levels were not very high, probably because participants' diabetes was well-controlled without insulin treatment in the participants. Therefore, the findings of our study should be interpreted with caution.
MATERIALS AND METHODS
Study design and patients
The rationale and design of the PROLOGUE study (University Hospital Medical Information Network Center: ID 000004490) have been described previously [34] . The PROLOGUE study was a multicenter, prospective, randomized, open-label trial and blinded-endpoint trial carried out with the participation of 48 Japanese institutions. Eligible patients were at least 30 years of age who had type 2 diabetes with an HbA1c level of 6.2-9.4% despite conventional treatment with diet, exercise and/ or pharmacological therapy with oral antihyperglycemic agents (except incretin-related therapy) for more than 3 months. Patients who had taken a DPP-4 inhibitor, such as glucagon-like peptide-1 (GLP-1) analogs, or insulin before randomization were excluded. Other exclusion criteria are described elsewhere. www.impactjournals.com/oncotarget Between June 2011 and September 2012, a total of 463 patients with type 2 diabetes were enrolled in the PROLOGUE study and randomly assigned in a 1:1 ratio to either add-on sitagliptin treatment (sitagliptin group: n=232) or conventional antihyperglycemic treatment (conventional group: n=231). The treatment randomization was based on age, gender, use of statins, pretreatment diabetic type (non-pharmacological or pharmacological treatment), HbA1c level (<7 or ≥7%), office systolic blood pressure (<135 or ≥135 mm Hg), and maximum IMT (<1.0 or ≥1.0 mm) [35] . All patients were treated with the aim of achieving a targeted HbA1c level of less than 6.2% or a fasting plasma glucose level of less than 110 mg/dL during the study period. Treatment of patients in the sitagliptin group initially began with sitagliptin at a dose of 50 mg daily. If further glycemic intervention was necessary, the dose of sitagliptin was increased up to 100 mg daily within 3 months, and conventional antihyperglycemic agents, other than DPP-4 inhibitors, GLP-1 analogs and/or insulin, were added. If further glycemic intervention was necessary in patients in the conventional group, antihyperglycemic agents, other than DPP-4 inhibitors, GLP-1 analogs and/or insulin, were added. All of the patients were followed up annually for 2 years until September 2014.
In the PROLOGUE study, the primary endpoint was the change in mean common carotid artery IMT at 24 months after treatment. Carotid ultrasound examinations were performed at the beginning of treatment and after 12 and 24 months of treatment. The secondary outcomes included changes in FMD in the brachial artery after 12 and 24 months of treatment. In all of the participating institutions, FBS, HbA1c, BP, DP, BUN and SCR were measured in all patients during an optional examination at the beginning of the study and after 12 and 24 months of treatment. Among the 463 participants in the PROLOGUE study, 365 patients were diagnosed with type 2 diabetes mellitus complicated with hypertension. One hundred and eighty-nine patients were randomly assigned to either add-on sitagliptin treatment (sitagliptin group) and 176 patients were randomly assigned to continue conventional treatment (conventional group). The data for these 365 patients were analyzed in our study. This sub-study is a pre-specified analysis. The ethical committees of the participating institutions approved the study protocol. Written informed consent for participation in the study was obtained from each subject.
Study protocol
All studies were performed in the morning, after overnight fasting, in a quiet, dark, and air-conditioned room (constant temperature of 22-25 °C) . The subjects were kept in the supine position throughout the study. The observers were blind to the type of treatment.
Clinical and other measurements
The same protocol for measuring FMD in the brachial artery was used in our study. Height and weight were measured and body mass index (BMI, kg m −2 ) was calculated. At the time of the health examinations, after a brief period of rest, SBP and DBP were measured in either the right or left arm using a sphygmomanometer (Omron Corporation, Kyoto, Japan) with the participant in a sitting position. Blood pressure was measured once in most participants, but up to three measurements were taken at 1-2-min intervals in participants who had hypertensive or prehypertensive SBP and DBP values. The lowest reading was used in the analysis to assess the incidence of hypertension. Smoking habit and parental history of hypertension were assessed by a questionnaire, as was a self-reported history of hypertension. Blood samples were collected after an overnight fast, and measurements were made using an automatic clinical chemistry analyzer (Hitachi, LABOSPECT 008, Tokyo, Japan). FBS, HbA1c, BUN and SCR levels were measured using enzymatic methods at the beginning of the study and after 12 and 24 months of treatment.
Statistical analysis
Results are presented as the number (percent) or the mean±SD. Categorical variables were compared using the chi-square test. We compared the mean values of continuous variables between the 2 groups using student's unpaired t-test. Differences in the mean values of continuous variables between baseline, 12 months and 24 months were compared using repeated measures analysis of variance.
In the analysis comparing the treatment effects, the baseline-adjusted means and their 95% CIs, as estimated by analysis of covariance (ANCOVA), were compared between the two groups. This analysis was carried out while considering the variation caused by treatment effects. Furthermore, a multivariate regression analysis was conducted for adjusting confounding factors, such as age, body height, body weight, DBP, SBP, creatinine, heart rate, uric acid, total cholesterol, fasting plasma glucose, HDL, blood urea nitrogen, HBA1C, cystatin-C, triglyceride, waist circumferences, small dense LDL, high molecular weight adiponectin, insulin, history of dyslipidemia, history of kidney disease, history of liver disease, history of cerebrovascular disorder, history of cardiovascular disorder, history of cerebral infarction, history of cerebral hemorrhage, history of transient ischemic attacks, history of cerebrovascular disorder, history of myocardial infarction, history of arrhythmia, history of percutaneous coronary intervention, history of heart failure, history of cardiovascular disorder, smoking habit, drinking habit, and history of coronary artery bypass graft.
